MACH-1™: Pow(d)ering your skin to deliver disease protection and treatment

Precise, localized powdered vaccines and immunotherapies

MACH-1 epidermal formulation and delivery platform

Why

Current approaches to vaccine and immunotherapy formulation and delivery are inefficient in targeting desired cells and tissues, leading to high doses, extra excipients and carriers, and possible off-target or side effects with subcutaneous (subQ) or intramuscular (IM) injections.  This is because they bypass the highly immunogenic and active skin–the body’s largest organ and a highly active immunology production and communication network beyond it’s obvious protective function. 

How

The skin drives how the body can respond to threats not only directly to the skin but also to other mucosal tissues (lung, gut, etc.).  The biomedical field is recognizing that targeting the skin, via intradermal (ID) administration, can be utilized more actively in preventing and treating disease in a manner that not only is effective but also minimizes off-target or safety concerns.  However, most ID methods still lack targeting efficiency needed to maximize efficacy and reduce side effects.

MACH-1 Technology

Our platform enables rapid vaccine production without cold chain requirements, leveraging $16.8M in NIH SBIR funding to advance DNA and RNA vaccines toward Phase 1 clinical trials.

MACH-1 Pipeline

Orlance MACH-1 vaccines and immunotherapies are being developed across multiple indications, with the program’s lead asset, a universal influenza vaccine, at pre-IND stage.

Executive Summary

MACH-1 has leveraged non-dilutive funding to reach Phase 1 trial readiness. The company is raising a $12M Series A in 2026 and seeking partners to develop an expanded portfolio of vaccine and immunotherapy assets. See summary

Intoducing MACH-1™

Next-Generation Vaccine Technology For Global Health

The MACH-1 platform delivers powdered nucleic acid vaccines directly into the epidermis, the skin’s most immunologically active layer. Our needle-free gene gun technology eliminates cold chain requirements, reduces vaccine doses by up to 90%, and triggers robust systemic and mucosal immunity.

Clinical Trails

Orlance anticipates initiating Phase 1 clinical trials for a universal influenza vaccine in 2027. Please check back soon for updates.

Latest News

Recent Milestones

  • $600K NIH awarded grant for vaccine development for chronic hepatitis B
  • $3.3M NIH grant awarded for enhanced seasonal influenza vaccine 
  • $1.4M Washington State Andy Hill CARE Fund grant for neoantigen cancer vaccine platform 

Upcoming Events

  • DARPA BIO Fair, June 2026
  • World Orphan Drug Congress, June 2026
  • BIO – San Diego, June 2026
  • Rapid Response Partnership Vehicle (RRPV) Membership Meeting, August 2026

Careers

Thank you for your interest in joining the Orlance team. While we currently do not have any openings, please check again another time.

Contact

Orlance Team

206-792-5527
info@orlance.com

Orlance Pipeline